

# The clinical utility of newer antidepressant agents: Understanding the role in management of MDD

Kristin Waters, PharmD, BCPS, BCPP<sup>1</sup>

**How to cite:** Waters K. The clinical utility of newer antidepressant agents: Understanding the role in management of MDD. *Ment Health Clin* [Internet]. 2022;12(5):309-19. DOI: 10.9740/mhc.2022.10.309.

**Submitted for Publication:** February 9, 2022; **Accepted for Publication:** July 7, 2022

## Abstract

Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non-mood-related symptoms of MDD. The 3 oral antidepressants that have been FDA-approved most recently include vortioxetine, vilazodone, and levomilnacipran. Unique features of these antidepressants are explored through 3 patient cases.

**Keywords:** antidepressants, major depressive disorder, psychopharmacology, treatment-emergent sexual dysfunction, cognitive impairment, depression-related fatigue

<sup>1</sup> (Corresponding author) Assistant Clinical Professor, University of Connecticut, Storrs, Connecticut, [kristin.waters@uconn.edu](mailto:kristin.waters@uconn.edu), ORCID: <https://orcid.org/0000-0002-2278-1018>

**Disclosures:** At the time of this writing, the Department of Veterans Affairs and Department of Defense Clinical Practice Guidelines for Management of Major Depressive Disorder 2022 had not yet been released. This guideline includes both vortioxetine and vilazodone as first-line treatment options for MDD. Also, I am a member of the Speaker's Bureau: Janssen Pharmaceuticals. I speak about medications that are not discussed in this article. Psychopharmacology Pearls are review articles intended to highlight both the evidence base available and/or controversial areas of clinical care for psychiatric and neurologic conditions as well as strategies of clinical decision making used by expert clinicians. As pearls, articles reflect the views and practice of each author as substantiated with evidence-based facts as well as opinion and experience. Articles are edited by members of the Psychopharmacology Pearls Editorial Board as well as peer reviewed by MHC reviewers. This article was developed as part of the 2022 Psychopharmacology Pearls product for BCPP recertification credit. The course information and testing center is at <https://aapp.org/503974>.

**Editor's Note:** This article was corrected in August 2023. The FDA approved paroxetine in 1992 (previously reported as 2001).

## Introduction

MDD is one of the most common psychiatric disorders in the United States affecting approximately 7% of adults.<sup>1</sup> This condition, characterized by periods of depressed mood and/or a loss of interest or pleasure, has a significant impact

on morbidity and mortality and represents a high economic burden.<sup>2-4</sup> Other symptoms of MDD may include changes in appetite, sleep patterns, energy, and concentration. Current trends indicate that antidepressant use is increasing in the United States. The percentage of Americans treated with an antidepressant increased by approximately 65% from 1999-2002 to 2011-2014.<sup>5</sup> The most recently available data (2015-2018) indicates that 13.2% of adults in the United States reported taking an antidepressant medication within the past 30 days.<sup>6</sup>

Despite the more widespread use of antidepressants, few new agents have become available in recent decades (see Table 1 for FDA approval dates). The most commonly prescribed medications remain the SSRIs.<sup>7</sup> Additional first-line treatments include SNRIs, bupropion, and mirtazapine.<sup>8-10</sup> The 2016 Canadian Network for Mood and Anxiety Treatments (CANMAT) guideline also includes vortioxetine as a first-line treatment option.<sup>8</sup> Second- and third-line options include tricyclic antidepressants; monoamine oxidase inhibitors; nonpharmacologic treatments, such as electroconvulsive therapy or transcranial magnetic stimulation; and augmentation with nonantidepressant medications, such as lithium or second-generation antipsychotics.<sup>8-10</sup>



**TABLE 1: FDA-approved first-line and newer oral antidepressants for MDD**

Generic Medication Name	Year of FDA Approval
SSRIs	
Citalopram	1998
Escitalopram	2002
Fluoxetine	1987
Paroxetine	1992
Sertraline	1991
Vilazodone <sup>a</sup>	2011
Vortioxetine <sup>b</sup>	2013
SNRIs	
Desvenlafaxine	2008
Duloxetine	2004
Levomilnacipran	2013
Venlafaxine	1997
Norepinephrine dopamine reuptake inhibitors	
Bupropion	1985
Tetracyclic antidepressants	
Mirtazapine	1997

<sup>a</sup>SSRI and 5HT<sub>1A</sub> partial agonist.

<sup>b</sup>SSRI and 5HT<sub>1A</sub> agonist; 5HT<sub>1B</sub> partial agonist; 5HT<sub>1D</sub>, 5HT<sub>3A</sub>, 5HT<sub>7</sub> antagonist.

The focus of this article is the most recently FDA-approved oral medications for the treatment of MDD, including vilazodone, vortioxetine, and levomilnacipran. Although these medications have been FDA-approved for approximately 10 years, clinicians may be less familiar with these agents. Unique properties, including adverse effects and potential role in therapy, are addressed in this article in 3 patient cases.

### Case 1: MDD and Antidepressant-Related Sexual Dysfunction

A 38-year-old female patient with a past medical history of generalized anxiety disorder (GAD), type II diabetes mellitus, obesity, and MDD presents to her outpatient psychiatrist. Active home medications include escitalopram 20 mg daily and metformin 500 mg twice daily. Escitalopram was initiated approximately 4 months ago and has contributed to a significant improvement of both GAD and MDD symptoms. However, the patient is experiencing anorgasmia and decreased libido, which has been affecting the patient's relationship with her partner. The patient recalls significantly elevated levels of anxiety and insomnia in the past when trialed on bupropion XL.

Sexual dysfunction, including problems with libido, arousal, orgasm, and ejaculation, may be caused or worsened by MDD in the absence of pharmacologic treatment.<sup>11,12</sup>

### Take Home Points:

1. Non-mood-related symptoms of MDD can cause significant impairment and may not be adequately treated by standard treatment options. These symptoms can include sexual dysfunction, cognitive impairment, and depression-related fatigue.
2. The most recently FDA-approved oral antidepressants include vortioxetine, vilazodone, and levomilnacipran. It is hypothesized that these medications may be able to better target these non-mood-related symptoms of MDD.
3. Current data assessing unique features of these newer antidepressants demonstrate relatively low clinical significance compared with typical first-line treatment, including SSRIs and SNRIs.

Antidepressants may contribute to treatment-emergent sexual dysfunction (TESD).<sup>13,14</sup> It is estimated that as many as 70% of patients treated with an SSRI experience TESD, which contributes to antidepressant nonadherence.<sup>13,15</sup> The mechanism by which antidepressants contribute to sexual dysfunction remains poorly understood. Activation of 5HT<sub>2A</sub> receptors in the central serotonergic system is likely a factor.<sup>16</sup> Serotonergic activation may also reduce dopamine transmission in the mesolimbic area. Dopamine is known to have a positive effect on sexual functioning.<sup>13,14,16</sup> Pharmacologic management of TESD may include short-term interruption of dosing (*drug holidays*); changing the administration time; switching to another antidepressant with less serotonergic activity, such as bupropion or mirtazapine; decreasing the dose of the antidepressant; or initiating add-on treatment.<sup>17</sup> Add-on treatments may include a second antidepressant, such as bupropion, or a 5HT<sub>2A</sub> antagonist, such as mirtazapine, although mirtazapine's adverse effect profile may limit its use for patients when sedation and appetite stimulation are not desired. In cases of erectile dysfunction in male patients, a phosphodiesterase type 5 inhibitor, such as sildenafil, may also be added. The partial 5HT<sub>1A</sub> agonist buspirone may also be used although data are mixed in terms of its effect on sexual dysfunction caused by SSRI treatment.<sup>16-18</sup>

Vilazodone was first approved by the FDA in 2011 primarily based on the results of 2 phase III randomized placebo-controlled trials.<sup>19,20</sup> Whereas it is generally considered an SSRI, vilazodone also acts as a partial agonist of presynaptic 5HT<sub>1A</sub> receptors.<sup>21</sup> This combined mechanism of action mimics the combination of an SSRI plus buspirone, another 5HT<sub>1A</sub> partial agonist, although with different binding capacities. The combination of an SSRI/SNRI and buspirone results in 10% to 20% occupation of the 5HT<sub>1A</sub> receptors and 80% inhibition of the serotonin transporter (SERT)

compared with vilazodone's ability to occupy 50% of both 5HT<sub>1A</sub> receptors and SERT.<sup>22,23</sup> Vilazodone's partial agonism of the presynaptic 5HT<sub>1A</sub> autoreceptors may enhance the serotonergic effect, and it was hypothesized that this would contribute to a more rapid onset of symptom relief and greater efficacy. The partial agonism of these receptors was hypothesized to reduce the degree of sexual dysfunction associated with SSRIs.<sup>21,24,25</sup> Although animal models did demonstrate a more rapid elevation of synaptic serotonin compared with SSRIs, the anticipated rapid onset of clinical effect and greater efficacy has not been demonstrated in head-to-head human trials.<sup>22,27</sup> The rapid serotonin increase may also contribute to the higher prevalence of serotonin-mediated nausea and vomiting more commonly associated with vilazodone (20% to 30%) as compared with other SSRIs.<sup>28,29</sup>

The post hoc analysis of a randomized, double-blind, active-controlled phase IV clinical trial compared the impact on sexual functioning of vilazodone at doses of 20 and 40 mg/d with citalopram 40 mg/d and placebo.<sup>15,28</sup> The abbreviated version of the Changes in Sexual Functioning Questionnaire (CSFQ-14) was utilized to assess 1047 outpatients with MDD experiencing a current depressive episode. The CSFQ-14 is a validated, 14-item, sex-specific, self-reported scale that was developed to assess changes in sexual functioning associated with psychiatric illnesses or medications.<sup>29</sup> The total score ranges from 14 to 70 with lower scores indicating more sexual dysfunction.<sup>32,33</sup> A score of  $\leq 47$  and  $\leq 41$  represent clinically significant sexual dysfunction in males and females, respectively. In this study, patients in all groups demonstrated an improvement in CSFQ-14 scores from baseline to week 10 of treatment with a greater improvement in subjects who were considered treatment responders (based on Montgomery-Åsberg Depression Rating Scale [MADRS] scores; see Table 2). Subjects with baseline sexual dysfunction ( $>50\%$  of subjects) had greater improvements in CSFQ-14 scores, whereas the change in subjects with normal baseline sexual functioning was small. The mean changes in total CSFQ-14 score were relatively small in all groups. No groups showed statistically significant improvement in CSFQ-14 scores compared with placebo in the original study, and no inferential statistics were performed in the post hoc analysis. Although a minimal clinically important difference in CSFQ-14 scores has not been definitively established, it is sometimes cited as a change in 3 to 5 points.<sup>39,40</sup> Therefore, minimal clinical improvement was demonstrated in this analysis. The rates of decreased libido and delayed ejaculation identified are similar to those associated with bupropion, an antidepressant generally not associated with TESD.<sup>41</sup> Therefore, the rates of TESD identified in this comparison trial with vilazodone and citalopram identified relatively low rates of TESD in all groups. No subjects discontinued vilazodone due to TESD. Although this study showed a trend toward less TESD in the vilazodone groups, the results were not statistically signif-

icant. It should also be noted that antidepressants with high serotonin selectivity, which include citalopram along with fluoxetine, paroxetine, sertraline, and venlafaxine, are associated with higher rates of sexual dysfunction compared with other less selective antidepressants.<sup>36</sup> Despite the use of citalopram as a control in this study, there was still no clinically significant difference in TESD.

A phase I, randomized, double-blind, parallel-group study<sup>37</sup> assessed the impact of placebo, paroxetine 20 mg/d, and vilazodone 20 or 40 mg/d on sexual functioning in healthy, sexually active volunteers aged 18 to 45 years. The primary outcome was the change in CSFQ-14 scores from baseline to day 35. Whereas the CSFQ-14 scores did decrease (worsen) in all groups, there were no statistically significant differences. A post hoc analysis that excluded patients in the active treatment groups with an undetectable plasma drug concentration demonstrated that the paroxetine group experienced a more significant decrease in CSFQ-14 total of  $-10.5$  compared with  $-1.14$  and  $-0.78$  in the placebo and vilazodone 20 mg/d groups, respectively ( $P < .05$ ). Thus, neither comparative trial including vilazodone demonstrated a statistically significant difference in sexual functioning in the primary analysis despite comparison with antidepressants generally associated with a higher rate of TESD.

Vortioxetine has also been investigated for a potentially lower incidence of TESD. It was FDA-approved in 2013 based on the results of 6 short-term (6 to 8 week) randomized, double-blind, placebo-controlled clinical trials and 1 maintenance study, which demonstrated efficacy in the treatment of MDD.<sup>38</sup> In addition to the inhibition of SERT, it antagonizes 5HT<sub>3</sub>, 5HT<sub>7</sub>, and 5HT<sub>1D</sub> receptors. Additional mechanisms include partial agonist activity at 5HT<sub>1B</sub> receptors and agonist activity at 5HT<sub>1A</sub> receptors.<sup>39,40</sup> These additional serotonergic mechanisms may contribute to the high rate of nausea (15% to 20%) associated with vortioxetine.<sup>38</sup> Early trials<sup>37,41</sup> suggest that vortioxetine had similar rates of sexual dysfunction as placebo. One study included patients with adequately treated MDD who experienced TESD as measured by CSFQ-14 during treatment with citalopram, paroxetine, or sertraline.<sup>42,43</sup> These patients were randomly assigned to switch directly to flexible doses (10 or 20 mg/d) of vortioxetine ( $n = 225$ ) or escitalopram ( $n = 222$ ). The primary endpoint was the change in CSFQ-14 total score from baseline to the end of 8 weeks of treatment. Patients in the vortioxetine group showed statistically significant mean improvement in CSFQ-14 scores ( $8.8 \pm 0.64$ ) compared with escitalopram ( $6.6 \pm 0.64$ ;  $P = .013$ ). This difference was also significant at week 4. If a 3- to 5-point improvement is to be considered the minimal threshold for clinical improvement, this study demonstrates meaningful improvement in TESD in both groups. Several studies<sup>44,45</sup> also compared the rate of TESD associated with vortioxetine with that of duloxetine. One of these studies<sup>45</sup> compared the

**TABLE 2: Changes in sexual functioning from post hoc analysis (baseline to week 10)**

	Results							
	Female				Male			
	n (mean change in total CSFQ-14 score)	Libido decreased, %	Erectile dysfunction, %	Delayed ejaculation, %	n (mean change in total CSFQ-14 score)	Libido decreased, %	Erectile dysfunction, %	Delayed ejaculation, %
Placebo (n = 264)								
All females	147 (2.0)	0.6	0	0	117 (3.5)	0.6	2.4	0
MADRS responders	58 (3.84)				49 (4.35)			
MADRS nonresponders	60 (0.27)				45 (2.6)			
Normal sexual function at baseline	46 (-1.09)				48 (0.71)			
Sexual dysfunction at baseline	72 (4.01)				46 (6.43)			
Vilazodone 20 mg/d (n = 267)								
All females	152 (1.9)	1.8	0	0	115 (2.4)	2.5	0	0.8
MADRS responders	73 (3.82)				56 (3.21)			
MADRS nonresponders	41 (-1.41)				31 (0.97)			
Normal sexual function at baseline	44 (-1.48)				37 (0.41)			
Sexual dysfunction at baseline	70 (4.09)				50 (3.90)			
Vilazodone 40 mg/d (n = 259)								
All	148 (3.0)	0.6	0	0	111 (1.2)	3.3	2.4	1.6
MADRS responders	70 (5.06)				54 (2.26)			
MADRS nonresponders	38 (-0.87)				30 (-0.80)			
Normal sexual function at baseline	33 (-0.55)				37 (-0.95)			
Sexual dysfunction at baseline	75 (4.52)				47 (2.83)			
Citalopram 40 mg/d (n = 257)								
All	148 (1.2)	1.2	0	0	109 (2.1)	1.7	2.6	1.7
MADRS responders	72 (2.33)				57 (2.67)			
MADRS nonresponders	50 (-0.42)				26 (0.77)			
Normal sexual function at baseline	41 (-1.05)				37 (0.32)			
Sexual dysfunction at baseline	81 (2.35)				46 (3.48)			

CSFQ-14 = Changes in Sexual Functioning Questionnaire; MADRS = Montgomery-Åsberg Depression Rating Scale.

rate of TESD using the Arizona Sexual Experiences Scale (ASEX) in adult patients age 18 to 75 years with MDD over an 8-week period. The ASEX is a validated 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, and ability to reach orgasm. Possible total scores range from 5 to 30. Sexual dysfunction is considered a total score  $\geq 19$ , a single item score of 5 or 6, or any 3 items having a score of  $\geq 4$ .<sup>46</sup> Although the results show a trend toward a lower rate of TESD in the vortioxetine 15 mg/d, vortioxetine 20 mg/d, and placebo groups (35.6%, 35.6%, 36.2%, respectively) compared with the duloxetine 60 mg/d group (53.2%), these results were not statistically significant. A second study, which included adults 18 to 75 years of age with MDD, conducted an exploratory analysis of sexual function utilizing the ASEX. Participants in this study had a high rate (65% to 71.2%) of sexual dysfunction at baseline. The rate of TESD among subjects without baseline sexual

dysfunction was highest in the vortioxetine 2.5 mg/d group (51%) compared with vortioxetine 5 mg/d (37.5%), duloxetine 60 mg/d (46.9%), and placebo (33.3%).<sup>44</sup> None of the changes in ASEX score from baseline were significant compared with placebo in any group after 6 or 8 weeks.

An additional randomized, double-blind, parallel group, phase IV study used the CSFQ-14 as a primary endpoint when comparing TESD rates in healthy adults (age 18 to 40 years) treated with paroxetine 20 mg/d, vortioxetine 10 mg/d, vortioxetine 20 mg/d, or placebo.<sup>47</sup> In this study (n = 361), paroxetine was associated with significantly more TESD than vortioxetine 10 mg/d (mean difference of 2.74 points,  $P = .009$ ) after 5 weeks of treatment in all 5 dimensions of the CSFQ-14. Vortioxetine 20 mg/d showed numerical improvements in TESD compared with placebo, but the difference was not statistically significant. Neither

dose of vortioxetine was statistically significantly worse than placebo in terms of TESD, whereas paroxetine did cause significantly more TESD.

This case demonstrates the importance of considering sexual dysfunction a constellation of symptoms that may affect patients with MDD regardless of medication status. TESD may have a profound impact on antidepressant adherence rates. For this particular patient, a medication change should be considered in an attempt to alleviate the reported TESD. While switching to or adding bupropion may be a reasonable intervention for some patients, this patient has previously experienced an increase in GAD symptoms following bupropion initiation. Because the patient is a biological female, it would also not be appropriate to recommend a phosphodiesterase type 5 inhibitor. Mirtazapine, although also less likely to induce TESD, may also not be the best option due to the patient's type II diabetes mellitus and obesity. Vortioxetine is not associated with any known weight gain, whereas the rate associated with vilazodone is low at 1% to 2%.<sup>29,38</sup> Therefore, it may be reasonable to consider either vilazodone or vortioxetine. Because vortioxetine is considered a first-line treatment option per the CANMAT guidelines and because it was directly compared to escitalopram (this patient's current medication), it may be a better initial choice.

## Case 2: Depression-Related Cognitive Impairment

A 45-year-old patient with MDD has achieved partial remission from treatment with venlafaxine XR 300 mg daily for 6 months. Previous trials include citalopram, sertraline, mirtazapine, and duloxetine. Although noting a significant improvement in mood, appetite, and sleep, the patient reports extreme difficulty concentrating at work. In addition, tasks that were once simple and routine are taking much more time and mental effort. The patient is worried about being demoted or terminated if quality of work does not improve.

The cognitive dysfunction often associated with MDD plays a significant role in a patient's ability to maintain activities of daily living and full-time employment.<sup>38,48</sup> A post hoc analysis<sup>49</sup> of the STAR\*D trial shows that negative mood and concentration problems were the most debilitating depressive symptoms for all domains of functioning. Additional data<sup>50,51</sup> support this and identify that people with MDD experienced the most prominent impairment in domains of executive functioning, processing speed, concentration and attention, learning, and memory. While notable during an acute episode, these deficiencies are also found to persist during remission from mood symptoms.<sup>51-53</sup>

Vortioxetine, in addition to the mechanisms previously discussed, demonstrates the ability to increase extracellular acetylcholine and histamine levels while selectively increasing dopamine levels in the frontal cortex and nucleus accumbens.<sup>39,54,55</sup> Glutamatergic, noradrenergic, and GABAergic systems are also modulated by vortioxetine.<sup>56,57</sup> Although the exact mechanisms are not clear, the actions on these neurotransmitter systems may account for the potential improvements in cognition and anxiolytic effects seemingly unique to vortioxetine.<sup>56</sup>

Vortioxetine's impact on cognitive functioning and/or functional recovery from MDD has been an area of study as the goal of treatment has shifted to include improvement of cognitive symptoms and return to functional productivity. The CONNECT study was a multicenter, double-blind, parallel-group, placebo-controlled trial that compared the effect of vortioxetine or placebo on cognitive functioning for patients with acute recurrent MDD. This was measured via the Digit Symbol Substitution Test (DSST), which assesses processing speed, executive function, and attention.<sup>58</sup> This scale ranges from 0 to 133 points with a lower score indicating worse cognitive functioning. The degree of change in the DSST score is typically represented using a standard effect size statistic. The clinical significance of changes in DSST score in MDD is typically measured by how far the SD score is below the norm; however, DSST scores do not always correlate with patient-reported depression score in patients with MDD.<sup>63,64</sup> The primary endpoint of this study was the change in DSST from baseline to week 8 for patients receiving flexible-dose vortioxetine (10 or 20 mg/d), duloxetine (60 mg/d), or placebo. Compared with placebo, vortioxetine demonstrated a significant improvement of 1.75 points in the DSST score with a standardized effect size of 0.254 indicating small-to-moderate improvement. The change in DSST was not significantly different in the duloxetine group compared with placebo (change of 1.21). However, the small numerical difference in change in DSST score between the groups suggests there may be no clinically significant difference. A post hoc analysis was also designed to measure depressive symptoms (measured via MADRS) along with patient function as evaluated by the University of California San Diego Performance-based Skills Assessment (UPSA).<sup>48,58</sup> This test involves role-playing tasks in 5 functional areas, including communication, finance, and transportation. It is validated as a test of functioning in MDD and is correlated with cognitive function and work ability but may change independently of depressive symptoms.<sup>59</sup> An increase of 6 to 7 points after 8 weeks of antidepressant treatment is considered the threshold for clinical relevance.<sup>60,61</sup> This analysis identified patients who were considered dual responders, meaning that they had achieved  $\geq 50\%$  reduction in baseline MADRS score plus a change in the UPSA composite score of  $\geq 7$  points by the end of 8 weeks. The vortioxetine group had a significantly greater number of

dual responders (27.4%) compared with the placebo group (14.5%,  $P=.004$ ). The calculated number needed to treat (NNT) is 8. The duloxetine group ( $n=210$ ) did not have a statistically significantly different percentage of dual responders (22.5%, NNT of 13) than the placebo group. The vortioxetine group also showed statistically significant improvement (23.4%, NNT of 11) compared with placebo (13.9%,  $P=.025$ ) when the UPSA composite score threshold was increased to  $\geq 9$ , whereas the duloxetine group did not. The authors concluded that vortioxetine treatment resulted in a greater probability of achieving a combined symptomatic/functional outcome.

The ReMind SWITCH study was a randomized, active-comparator, parallel-group trial<sup>62</sup> that included patients with MDD with an inadequate response to  $\geq 6$  weeks of SSRI or SNRI monotherapy. This study compared the effects of vortioxetine ( $n=51$ ) and escitalopram ( $n=50$ ), both flexibly dosed at 10 to 20 mg/d, on cognitive dysfunction and MDD symptoms over 8 weeks of treatment on the DSST. All cognitive performance tests conducted in this study (including secondary efficacy assessments) were also combined into a composite score to measure overall cognitive performance. The DSST score improved by 8.46 and 6.46 in the vortioxetine and escitalopram groups, respectively, with a mean difference of 2.0 points in favor of vortioxetine. The standardized effect size was 0.25 for vortioxetine versus escitalopram, indicating a small-to-moderate improvement. However, none of these results was statistically significant. Secondary outcome measures tended to favor vortioxetine regarding impact on cognitive functioning, but again, no statistically significant differences were noted. This relatively small study suggests that both vortioxetine and escitalopram improve cognitive function in patients with MDD who failed to respond to previous treatment.

The ReMind WORK study was a small ( $N=152$ ), exploratory, multisite, randomized, parallel-group, placebo-controlled trial that included patients aged 18 to 65 years with MDD (MADRS score  $\geq 26$ ) who were actively working.<sup>65</sup> Patients were randomized to 8 weeks of treatment with either vortioxetine 10 mg/d, paroxetine 20 mg/d, or placebo. The DSST score (primary outcome) increased in all treatment groups (7.37, 7.59, 6.61 in the placebo, vortioxetine, and paroxetine groups, respectively) but with no statistical differences noted. One of the secondary measures in this study was the Perceived Deficits Questionnaire-Depression (PDQ-D) score. The PDQ-D is a subjective measure and is measured on a scale from 0 to 80 with higher scores indicating more severe symptoms. Both vortioxetine, with a difference of -6.81 ( $P=.012$ ) and paroxetine with a difference of -6.91 ( $P=.010$ ) showed statistically significant improvement in this measure compared with placebo. A limitation of the PDQ-D score is that cutoff values are not definitely established although a

change of approximately 7 points out of a potential score of 80 may not constitute a clinically significant change.<sup>66</sup>

Vortioxetine is also studied as a potential adjunctive treatment to standard SSRI therapy to improve cognitive impairment in MDD.<sup>67</sup> One randomized, double-blind, placebo-controlled trial included patients in remission or partial remission from MDD following  $\geq 12$  weeks of treatment with SSRI monotherapy (escitalopram, citalopram, or sertraline) at a stable dose for  $\geq 8$  weeks before screening. Subjects were then randomized to current SSRI plus placebo (SSRI monotherapy), current SSRI plus vortioxetine (vortioxetine adjunctive treatment), or vortioxetine plus placebo (vortioxetine monotherapy). The DSST score was the primary efficacy measure. Several other cognitive function assessments were included as secondary endpoints, including the Rey Auditory Verbal Learning Test, Sheehan Disability Scale (SDS), Trail Making Test A and B, and the Stroop Color Naming Test. By the end of 8 weeks, the DSST core had improved similarly in all treatment groups with no differences identified. Similar results were seen in secondary endpoint measures although numerically greater improvements were seen in some endpoints, such as SDS scores, in both vortioxetine groups compared with the SSRI monotherapy group.

Overall, whereas it appears that vortioxetine is efficacious in the treatment of MDD, the evidence supporting its ability to target cognitive dysfunction is mixed. For the patient in this case, it may be reasonable to trial vortioxetine monotherapy given the multiple previous trials of both SSRIs and SNRIs and persistent cognitive symptoms. Furthermore, the patient is only experiencing a partial response, so a medication change may be warranted regardless of cognitive status.

### Case 3: Depression-Related Fatigue

A 32-year-old patient with MDD presents to the outpatient clinic due to a new depressive episode. This is the third total lifetime episode. Previous episodes have been successfully treated with venlafaxine XR 225 mg/d. The patient notes that this episode feels different because the most prominent symptoms are fatigue and a significant lack of motivation to succeed at work and to socialize with friends. The patient states that, if given the chance, the patient would lay on the couch all day.

Some symptoms of MDD may be more specifically related to a deficiency in norepinephrine (NE). These symptoms include fatigue, amotivation, anhedonia, and apathy.<sup>68,69</sup> Fatigue may be one of the most common factors impacting daily functioning in MDD, affecting more than 90% of patients. Fatigue may also significantly reduce the likelihood of remission from a depressive episode.<sup>70-72</sup> In a secondary

analysis of the STAR\*D trial, 60.8% of patients demonstrated residual fatigue after up to 14 weeks of treatment with an SSRI. Patients with residual fatigue also had worse mental and physical functioning outcomes compared with patients with remission of fatigue symptoms.<sup>71</sup>

Levomilnacipran extended-release (ER) was FDA-approved for MDD in 2013.<sup>73,74</sup> Unlike more commonly utilized SNRIs, levomilnacipran shows significant selectivity for inhibition of NE reuptake compared with serotonin (2:1 inhibition ratio). Levomilnacipran's selectivity for NE as opposed to serotonin is 17 times higher than venlafaxine and 27 times higher than duloxetine. This is a dose-related phenomenon, and at higher doses, levomilnacipran inhibits NE and serotonin transporters equally.<sup>68,75</sup> Levomilnacipran does not appear to have activity at other receptor types, such as dopaminergic, muscarinic, or adrenergic receptors.<sup>73,76</sup> Similar to the other antidepressants discussed previously, levomilnacipran has a higher rate of nausea (17%) as compared with other common antidepressants.<sup>74</sup>

Because of levomilnacipran's high affinity for NE receptors, the possibility that this medication could have more efficacy in NE deficiency-related symptoms of MDD has been explored. Although studies of levomilnacipran ER were not specifically designed to assess its impact on fatigue-related symptoms, several post hoc analyses<sup>77-81</sup> have been conducted using the results of the same 5 randomized, double-blind, placebo-controlled trials of levomilnacipran ER 40 to 120 mg daily for MDD. One post hoc analysis<sup>70</sup> included 2598 subjects and focused on the effect of levomilnacipran on fatigue symptoms as measured by the change in least squares mean (LSM) from baseline to the end of double-blind treatment of several fatigue-related scales. These included item 7 of the MADRS scale (lassitude, described as difficulty or slowness in initiating and/or performing daily activities) and items 7, 8, and 13 of the Hamilton Depression Rating Scale (HAMD<sub>17</sub>), which measure work/activities, psychomotor retardation, and general somatic symptoms respectively. Patients were categorized based on whether they had high (MADRS item 7 score  $\geq 4$ ) or low (MADRS item 7 score  $< 4$ ) levels of fatigue prior to treatment. The majority of patients (73.8%) met criteria for high levels of fatigue. Mean baseline MADRS total scores were also higher in this group. The results of this post hoc analysis showed statistically significant improvements in the levomilnacipran ER group in all 4 fatigue-related scales compared with placebo in both the high and low fatigue level groups ( $P < .05$ ). However, the effect sizes were small, ranging from 0.09 (psychomotor retardation) to 0.21 (work/activities). The percentage of patients in the overall study population with remission of fatigue symptoms was also greater for patients receiving levomilnacipran for all MADRS and HAMD<sub>17</sub> items ( $P < .05$ ). Treatment effect sizes differed across some subgroups. Male patients and older patients had a greater

effect size than female and younger patients, respectively. Premenopausal females ( $< 50$  years of age) also had a greater effect size compared with women older than 50 years. Obese patients with a BMI  $\geq 30$  kg/m<sup>2</sup> did not have a detectable difference in fatigue symptoms compared with placebo.

Another post hoc analysis of the same 5 trials divided patients into subgroups according to baseline symptom clusters if present.<sup>82</sup> The noradrenergic cluster (NA Cluster) included patients with higher baseline scores in items from the MADRS and HAMD<sub>17</sub> scales related to concentration difficulties (High NA Subgroup). The Anxiety Cluster included subjects with higher baseline scores in items pertaining to inner tension, agitation, psychic anxiety, and somatic anxiety (High Anxiety Subgroup). A third subgroup contained patients who met criteria for both clusters (High NA + Anxiety Subgroup). The LSM changes from baseline were significantly greater in both the NA and Anxiety Cluster scores in the levomilnacipran ER group compared with placebo. These results were significant for all 6 of the items making up the NA Cluster score (effect size 0.15 to 0.24) and 3 of the 4 items making up the Anxiety Cluster score (effect size 0.10 to 0.16); there was no significant difference in HAMD<sub>17</sub> item 11, which assesses somatic anxiety. All 3 subgroups demonstrated a statistically significant decrease in the NA Cluster score with a greater effect in the High NA and High NA + Anxiety groups (effect size 0.31 and 0.24, respectively). The Anxiety Cluster score decreased significantly for the High Anxiety and High NA + Anxiety Subgroups but not for the High NA subgroup. The response rate, defined as  $\geq 50\%$  improvement in cluster score, was significantly higher in the NA Cluster (44% vs 34%) and Anxiety Cluster (39% vs 36%) compared with placebo. Compared with the pooled study population, subjects in the 3 subgroups of this post hoc analysis demonstrated more functional improvement and a higher degree of improvement in NA and Anxiety Cluster scores.

Whereas the results of these post hoc analyses are promising, it would be difficult to select levomilnacipran solely based on fatigue or other NE-related symptoms, especially given the lack of any head-to-head comparisons of levomilnacipran with other antidepressants. Because this patient had a previous good response to venlafaxine XR, it would be reasonable to trial this medication again for the current depressive episode. Similar results may be expected in relation to NE-related symptoms because venlafaxine XR also inhibits the reuptake of NE in a dose-dependent manner.<sup>83</sup> Although not always the case, the majority of patients also do respond to reinstatement of an antidepressant that was previously effective.<sup>84</sup>

With the exception of the 2016 CANMAT guidelines, which include vortioxetine as a first-line treatment option and levomilnacipran and vilazodone as second-line options,

current guidelines do not explicitly recommend the 3 new antidepressants. Multiple meta-analyses<sup>85,86</sup> demonstrate minimal differences in overall efficacy between vilazodone, vortioxetine, levomilnacipran, and the other commonly utilized antidepressants. Whereas generally well-tolerated, vilazodone, vortioxetine, and levomilnacipran are all associated with an increased incidence of nausea compared with other antidepressants. None of the agents discussed are currently available generically in the United States, and they are generally considered “nonpreferred” treatment options on state Medicaid formularies. This may contribute to cost concerns for patients if the prescription is not covered by the insurance provider. Costs for these agents range from approximately \$400 to \$500 for a 30-day supply although savings programs are available.

## Conclusion

Patients with MDD may have significant variations in symptom presentation. Symptoms that are less commonly assessed, such as sexual dysfunction, cognitive impairment, and NE-related symptoms, such as fatigue, may have the most significant impact on a patient’s quality of life and functional abilities. As discussed in these patient cases, the more recently FDA-approved oral antidepressants may have unique features that are able to better target these symptoms of MDD. However, at this time, the data demonstrate relatively low clinical significance (vilazodone or vortioxetine for TSED), mixed results (vortioxetine for cognitive impairment), or are based on indirect comparisons (levomilnacipran for NE-related symptoms). Although these symptoms are important to consider when initiating an antidepressant for MDD, the 3 medications discussed in this article likely do not have enough compelling evidence to make a selection solely based on the unique features discussed.

## References

1. National Institute of Mental Health [Internet]. Major depression; 2017 [cited 2022 Jul]. Available from: <https://www.nimh.nih.gov/health/statistics/major-depression>
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington: American Psychiatric Association; 2013.
3. Greenberg PE, Fournier A-A, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). *J Clin Psychiatry*. 2015;76(2):155-62. DOI: [10.4088/JCP.14m09298](https://doi.org/10.4088/JCP.14m09298). PubMed PMID: [25742202](https://pubmed.ncbi.nlm.nih.gov/25742202/).
4. Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. *J Clin Psychiatry*. 2021;82(2):20m13699. DOI: [10.4088/JCP.20m13699](https://doi.org/10.4088/JCP.20m13699). PubMed PMID: [33989464](https://pubmed.ncbi.nlm.nih.gov/33989464/).
5. Pratt LA, Brody DJ, Gu Q. Antidepressant use among persons aged 12 and over: United States, 2011-2014. *NCHS Data Brief*. 2017; (283):1-8. PubMed PMID: [29155679](https://pubmed.ncbi.nlm.nih.gov/29155679/).

6. Brody DJ, Gu Q. Antidepressant use among adults: United States, 2015-2018. *NCHS Data Brief*. 2020;(377):1-8. PubMed PMID: [33054926](https://pubmed.ncbi.nlm.nih.gov/33054926/).
7. National Library of Medicine [Internet]. Commonly prescribed antidepressants and how they work; 2020 [cited 2022 Jul]. Available from: <https://magazine.medlineplus.gov/article/commonly-prescribed-antidepressants-and-how-they-work/>.
8. Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. *Can J Psychiatry*. 2016;61(9):540-60. DOI: [10.1177/0706743716659417](https://doi.org/10.1177/0706743716659417). PubMed PMID: [27486148](https://pubmed.ncbi.nlm.nih.gov/27486148/).
9. American Psychiatric Association [Internet]. Practice guideline for the treatment of patients with major depressive disorder; 2010 [cited 2022 Jul]. Available from: [www.psychiatryonline.org/pb/assets/raw/sitewide/practice\\_guidelines/guidelines/mdd.pdf](http://www.psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf)
10. Department of Veterans Affairs, Department of Defense. VA/DoD clinical practice guideline for the management of major depressive disorder; 2016 [cited 2022 Jul]. Available from: [www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPFINAL82916.pdf](http://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPFINAL82916.pdf)
11. Williams K, Reynolds MF. Sexual dysfunction in major depression. *CNS Spectr*. 2006;11(8 Suppl 9):19-23. DOI: [10.1017/s1092852900026729](https://doi.org/10.1017/s1092852900026729). PubMed PMID: [16871134](https://pubmed.ncbi.nlm.nih.gov/16871134/).
12. Thakurta RG, Singh OP, Bhattacharya A, Mallick AK, Ray P, Sen S, et al. Nature of sexual dysfunctions in major depressive disorder and its impact on quality of life. *Indian J Psychol Med*. 2012;34(4):365-70. DOI: [10.4103/0253-7176.108222](https://doi.org/10.4103/0253-7176.108222). PubMed PMID: [23723546](https://pubmed.ncbi.nlm.nih.gov/23723546/).
13. Keltner NL, McAfee KM, Taylor CL. Mechanisms and treatments of SSRI-induced sexual dysfunction. *Perspect Psychiatr Care*. 2002; 38(3):111-6. PubMed PMID: [12385082](https://pubmed.ncbi.nlm.nih.gov/12385082/).
14. Stahl SM. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. *J Clin Psychiatry*. 1998;59 Suppl 4:5-14. PubMed PMID: [9554316](https://pubmed.ncbi.nlm.nih.gov/9554316/).
15. Clayton AH, Gommoll C, Chen D, Nunez R, Mathews M. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial. *Int Clin Psychopharmacol*. 2015;30(4):216-23. DOI: [10.1097/YIC.000000000000075](https://doi.org/10.1097/YIC.000000000000075). PubMed PMID: [26039688](https://pubmed.ncbi.nlm.nih.gov/26039688/).
16. Rothmore J. Antidepressant-induced sexual dysfunction. *Med J Aust*. 2020;212(7):329-34. DOI: [10.5694/mja2.50522](https://doi.org/10.5694/mja2.50522). PubMed PMID: [32172535](https://pubmed.ncbi.nlm.nih.gov/32172535/).
17. Cai G, Jiang Z, Wang Z, Huang S, Chen K, Ge X, et al. Spatial aggregation net: point cloud semantic segmentation based on multi-directional convolution. *Sensors (Basel)*. 2019;19(19):4329. DOI: [10.3390/s19194329](https://doi.org/10.3390/s19194329). PubMed PMID: [31591349](https://pubmed.ncbi.nlm.nih.gov/31591349/).
18. Landén M, Eriksson E, Agren H, Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. *J Clin Psychopharmacol*. 1999;19(3):268-71. DOI: [10.1097/00004714-199906000-00012](https://doi.org/10.1097/00004714-199906000-00012). PubMed PMID: [10350034](https://pubmed.ncbi.nlm.nih.gov/10350034/).
19. Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. *J Clin Psychiatry*. 2011; 72(4):441-7. DOI: [10.4088/JCP.10m06596](https://doi.org/10.4088/JCP.10m06596). PubMed PMID: [21527122](https://pubmed.ncbi.nlm.nih.gov/21527122/).
20. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2009;70(3):326-33. PubMed PMID: [19284933](https://pubmed.ncbi.nlm.nih.gov/19284933/).
21. Schwartz TL, Siddiqui UA, Stahl SM. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. *Ther Adv Psychopharmacol*. 2011;



- 1(3):81-7. DOI: [10.1177/2045125311409486](https://doi.org/10.1177/2045125311409486). PubMed PMID: [23983930](https://pubmed.ncbi.nlm.nih.gov/23983930/); PubMed Central PMCID: [PMC3736894](https://pubmed.ncbi.nlm.nih.gov/PMC3736894/).
22. Hellerstein DJ, Flaxer J. Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. *Core Evid.* 2015;10:49-62. DOI: [10.2147/CE.S54075](https://doi.org/10.2147/CE.S54075). PubMed PMID: [25945081](https://pubmed.ncbi.nlm.nih.gov/25945081/).
  23. Rabiner EA, Gunn RN, Wilkins MR, Sargent PA, Mocaer E, Sedman E, et al. Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. *Nucl Med Biol.* 2000; 27(5):509-13. DOI: [10.1016/s0969-8051\(00\)00120-7](https://doi.org/10.1016/s0969-8051(00)00120-7). PubMed PMID: [10962259](https://pubmed.ncbi.nlm.nih.gov/10962259/).
  24. Stahl SM. *Stahl's essential psychopharmacology: neuroscientific and practical applications.* 4th ed. Cambridge: Cambridge University Press; 2011.
  25. Zheng G, Xue W, Yang F, Zhang Y, Chen Y, Yao X, et al. Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder. *Phys Chem Chem Phys.* 2017;19(42):28885-96. DOI: [10.1039/c7cp05688e](https://doi.org/10.1039/c7cp05688e). PubMed PMID: [29057413](https://pubmed.ncbi.nlm.nih.gov/29057413/).
  26. Williams K, Reynolds MF. Sexual dysfunction in major depression. *CNS Spectr.* 2006;11(8 Suppl 9):19-23. DOI: [10.1017/s1092852900026729](https://doi.org/10.1017/s1092852900026729). PubMed PMID: [16871134](https://pubmed.ncbi.nlm.nih.gov/16871134/).
  27. Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. *Eur J Pharmacol.* 2005;510(1-2):49-57. DOI: [10.1016/j.ejphar.2005.01.018](https://doi.org/10.1016/j.ejphar.2005.01.018). PubMed PMID: [15740724](https://pubmed.ncbi.nlm.nih.gov/15740724/).
  28. Citrome L. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out. *Int J Clin Pract.* 2015;69(2):151-5. DOI: [10.1111/ijcp.12620](https://doi.org/10.1111/ijcp.12620). PubMed PMID: [25627335](https://pubmed.ncbi.nlm.nih.gov/25627335/).
  29. Vilazodone [package insert]. Madison (NJ): Allergan USA, Inc; 2011.
  30. Matthews M, Gommoll C, Chen D, Nunez R, Khan A. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. *Int Clin Psychopharmacol.* 2015;30(2):67-74. DOI: [10.1097/YIC.000000000000057](https://doi.org/10.1097/YIC.000000000000057). PubMed PMID: [25500685](https://pubmed.ncbi.nlm.nih.gov/25500685/).
  31. Garcia-Portilla MP, Saiz PA, Fonseca E, Al-Halabi S, Bobes-Bascaran MT, Arrjojo M, et al. Psychometric properties of the Spanish version of the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) in patients with severe mental disorders. *J Sex Med.* 2011;8(5):1371-82. DOI: [10.1111/j.1743-6109.2010.02043.x](https://doi.org/10.1111/j.1743-6109.2010.02043.x). PubMed PMID: [20946156](https://pubmed.ncbi.nlm.nih.gov/20946156/).
  32. Clayton A, Durgam S, Tang X, Chen C, Ruth A, Gommoll C. Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies. *Neuropsychiatr Dis Treat.* 2016;2:1467-76. DOI: [10.2147/NDT.S103408](https://doi.org/10.2147/NDT.S103408). PubMed PMID: [27382289](https://pubmed.ncbi.nlm.nih.gov/27382289/).
  33. Bortolato B, Carvalho AF, McIntyre RS. Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review. *CNS Neurol Disord Drug Targets.* 2014;13(10):1804-18. DOI: [10.2174/1871527313666141130203823](https://doi.org/10.2174/1871527313666141130203823). PubMed PMID: [25470396](https://pubmed.ncbi.nlm.nih.gov/25470396/).
  34. Bobes J, Gonzalez MP, Bascaran MT, Clayton A, Moros F R-V, Banus S. Evaluating changes in sexual functioning in depressed patients: sensitivity to change of the CSFQ. *J Sex Marital Ther.* 2002;28(2):93-103. DOI: [10.1080/00926230252851852](https://doi.org/10.1080/00926230252851852). PMID: [11894800](https://pubmed.ncbi.nlm.nih.gov/11894800/).
  35. Ng L, Sansom J, Zhang N, Amatya B, Khan F. Effectiveness of a structured sexual rehabilitation programme following stroke: a randomized controlled trial. *J Rehabil Med.* 2017;49(4):333-40. DOI: [10.2340/16501977-2219](https://doi.org/10.2340/16501977-2219). PubMed PMID: [28350412](https://pubmed.ncbi.nlm.nih.gov/28350412/).
  36. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. *J Clin Psychopharmacol.* 2009;29(3):259-66. DOI: [10.1097/JCP.0b013e3181a5233f](https://doi.org/10.1097/JCP.0b013e3181a5233f). PubMed PMID: [19440080](https://pubmed.ncbi.nlm.nih.gov/19440080/).
  37. Clayton A, Durgam S, Dayong L, Chen C, Chen L, Laishun M, et al. Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study. *Int Clin Psychopharmacol.* 2017;32(1):27-35. DOI: [10.1097/YIC.0000000000000145](https://doi.org/10.1097/YIC.0000000000000145). PubMed PMID: [27643885](https://pubmed.ncbi.nlm.nih.gov/27643885/).
  38. Vortioxetine [package insert]. Deerfield (IL): Takeda Pharmaceuticals America, Inc; 2013.
  39. Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. *Expert Opin Drug Discov.* 2019;14(1):81-9. DOI: [10.1080/17460441.2019.1546691](https://doi.org/10.1080/17460441.2019.1546691). PubMed PMID: [30457395](https://pubmed.ncbi.nlm.nih.gov/30457395/).
  40. Westrich L, Pehrson A, Zhong H, Nielsen SM, Fredericksen K, Stensbøl TB, et al. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. *Int J Psychiatry Clin Pract.* 2012;16:47.
  41. Jacobsen PL, Mahableshwarkar AR, Palo WA, Chen Y, Dragheim M, Clayton AH. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. *CNS Spectr.* 2016;21(5):367-78. DOI: [10.1017/S1092852915000553](https://doi.org/10.1017/S1092852915000553). PubMed PMID: [26575433](https://pubmed.ncbi.nlm.nih.gov/26575433/).
  42. Jacobsen PL, Mahableshwarkar AR, Cheng Y, Chrones L, Clayton AH. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. *J Sex Med.* 2015;12(10):2036-48. DOI: [10.1111/jsm.12980](https://doi.org/10.1111/jsm.12980). PubMed PMID: [26331383](https://pubmed.ncbi.nlm.nih.gov/26331383/).
  43. Jacobsen PL, Nomikos GG, Zhong W, Cutler AJ, Affinito J, Clayton A. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. *CNS Spectr.* 2020;25(1):50-63. DOI: [10.1017/S1092852919000750](https://doi.org/10.1017/S1092852919000750). PubMed PMID: [31010445](https://pubmed.ncbi.nlm.nih.gov/31010445/).
  44. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. *Curr Med Res Opin.* 2013;29(3):217-26. DOI: [10.1185/03007995.2012.761600](https://doi.org/10.1185/03007995.2012.761600). PubMed PMID: [23252878](https://pubmed.ncbi.nlm.nih.gov/23252878/).
  45. Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. *Psychopharmacology (Berl).* 2015;232(12):2061-70. DOI: [10.1007/s00213-014-3839-0](https://doi.org/10.1007/s00213-014-3839-0). PubMed PMID: [25575488](https://pubmed.ncbi.nlm.nih.gov/25575488/).
  46. McGahuey CA, Gelenberg AJ, Laukes CA, Morena FA, Delgado PL, McKnight KM, Manber R. The Arizona Sexual Experience Scale (ASEX): reliability and validity. *J Sex Marital Ther.* 2000; 26(1):25-40. DOI: [10.1080/009262300278623](https://doi.org/10.1080/009262300278623). PubMed PMID: [10693114](https://pubmed.ncbi.nlm.nih.gov/10693114/).
  47. Jacobsen P, Zhong W, Nomikos G, Clayton A. Paroxetine, but not vortioxetine, impairs sexual functioning compared with placebo in healthy adults. *J Sex Med.* 2019;16(10):1638-49. DOI: [10.1016/j.jsxm.2019.06.018](https://doi.org/10.1016/j.jsxm.2019.06.018). PubMed PMID: [31405765](https://pubmed.ncbi.nlm.nih.gov/31405765/).
  48. Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders. *J Affect Disord.* 2018;227:787-94. DOI: [10.1016/j.jad.2017.11.081](https://doi.org/10.1016/j.jad.2017.11.081). PubMed PMID: [29689693](https://pubmed.ncbi.nlm.nih.gov/29689693/).
  49. Fried EI, Nesse RM. The impact of individual depressive symptoms on impairment of psychosocial functioning. *PLoS One.* 2014;9(2):e90311. DOI: [10.1371/journal.pone.0090311](https://doi.org/10.1371/journal.pone.0090311). PubMed PMID: [24587318](https://pubmed.ncbi.nlm.nih.gov/24587318/).
  50. Zukerman H, Pan Z, Park C, Brietzke E, Musial N, Shariq AS, et al. Recognition and treatment of cognitive dysfunction in major depressive disorder. *Front Psychiatry.* 2018;9:655. DOI: [10.3389/fpsy.2018.00655](https://doi.org/10.3389/fpsy.2018.00655). PubMed PMID: [30564155](https://pubmed.ncbi.nlm.nih.gov/30564155/).

51. Levada OA, Troyan AS. Cognitive-functional relationships in major depressive disorder: crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. *J Affect Disord.* 2019;250:114-22. DOI: [10.1016/j.jad.2019.03.040](https://doi.org/10.1016/j.jad.2019.03.040). PubMed PMID: [30852363](https://pubmed.ncbi.nlm.nih.gov/30852363/).
52. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. *Psychol Med.* 2011;41(6):1165-74. DOI: [10.1017/S0033291710001911](https://doi.org/10.1017/S0033291710001911). PubMed PMID: [20932356](https://pubmed.ncbi.nlm.nih.gov/20932356/).
53. Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. *J Affect Disord.* 2011;134(1-3):20-31. DOI: [10.1016/j.jad.2010.11.011](https://doi.org/10.1016/j.jad.2010.11.011). PubMed PMID: [21163534](https://pubmed.ncbi.nlm.nih.gov/21163534/).
54. Pehrson AL, Cremers T, Bétry C, van der Hart MGC, Jørgensen L, Madsen M, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—a rat microdialysis and electrophysiology study. *Eur Neuropharmacol.* 2013;23(2):133-45. DOI: [10.1016/j.euroneuro.2012.04.006](https://doi.org/10.1016/j.euroneuro.2012.04.006). PubMed PMID: [22612991](https://pubmed.ncbi.nlm.nih.gov/22612991/).
55. Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. *J Pharmacol Exp Ther.* 2012;340(3):666-75. DOI: [10.1124/jpet.111.189068](https://doi.org/10.1124/jpet.111.189068). PubMed PMID: [22171087](https://pubmed.ncbi.nlm.nih.gov/22171087/).
56. Frampton JE. Vortioxetine: a review in cognitive dysfunction in depression. *Drugs.* 2016;76(17):1675-82. DOI: [10.1007/s40265-016-0655-3](https://doi.org/10.1007/s40265-016-0655-3). PubMed PMID: [27807822](https://pubmed.ncbi.nlm.nih.gov/27807822/).
57. Sanchez C, Asini KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. *Pharmacol Ther.* 2015;145:43-57. DOI: [10.1016/j.pharmthera.2014.07.001](https://doi.org/10.1016/j.pharmthera.2014.07.001). PubMed PMID: [25016186](https://pubmed.ncbi.nlm.nih.gov/25016186/).
58. Mahableshwarkar AR, Zajacka J, Jacobson W, Chen Y, Keefe RSE. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. *Neuropsychopharmacology.* 2015;40(8):2025-37. DOI: [10.1038/npp.2015.52](https://doi.org/10.1038/npp.2015.52). PubMed PMID: [25687662](https://pubmed.ncbi.nlm.nih.gov/25687662/).
59. Harvey PD, Jacobson W, Zhong W, Nomikos GG, Christensen MC, Olsen CK, et al. Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder. *J Affect Disord.* 2017;213:105-11. DOI: [10.1016/j.jad.2017.02.014](https://doi.org/10.1016/j.jad.2017.02.014). PubMed PMID: [28213121](https://pubmed.ncbi.nlm.nih.gov/28213121/).
60. Christensen MC, Sluth LB, McIntyre RS. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: replication and extension of initial findings. *J Affect Disord.* 2019;245(9):508-16. DOI: [10.1016/j.jad.2018.11.034](https://doi.org/10.1016/j.jad.2018.11.034). PubMed PMID: [30439678](https://pubmed.ncbi.nlm.nih.gov/30439678/).
61. McIntosh BJ, Zhang XY, Kosten T, Tan SP, Xiu MH, Rakofsky J, et al. Performance-based assessment of functional skills in severe mental illness: results of a large-scale study in China. *J Psychiatr Res.* 2011;45(8):1089-94. DOI: [10.1016/j.jpsychires.2011.01.012](https://doi.org/10.1016/j.jpsychires.2011.01.012). PubMed PMID: [21300378](https://pubmed.ncbi.nlm.nih.gov/21300378/); PubMed Central PMCID: [PMC3112265](https://pubmed.ncbi.nlm.nih.gov/PMC3112265/).
62. Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: a short-term, randomized, double-blind, exploratory study versus escitalopram. *J Affect Disord.* 2018;227:803-9. DOI: [10.1016/j.jad.2017.11.053](https://doi.org/10.1016/j.jad.2017.11.053). PubMed PMID: [29673132](https://pubmed.ncbi.nlm.nih.gov/29673132/).
63. Wang G, Si T-M, Li L, Fang YR, Wang C-X, Wang L-N, et al. Cognitive symptoms in major depressive disorder: associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China. *Neuropsychiatr Dis Treat.* 2019;15:1723-36. DOI: [10.2147/NDT.S195505](https://doi.org/10.2147/NDT.S195505). PubMed PMID: [31308667](https://pubmed.ncbi.nlm.nih.gov/31308667/).
64. Jaeger J. Digit Symbol Substitution Test: the case for sensitivity over specificity in neuropsychological testing. *J Clin Psychopharmacol.* 2018;38(5):513-9. DOI: [10.1097/JCP.0000000000000941](https://doi.org/10.1097/JCP.0000000000000941). PubMed PMID: [30124583](https://pubmed.ncbi.nlm.nih.gov/30124583/).
65. Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: a short-term, randomized, double-blind, exploratory study. *J Affect Disord.* 2018;229:421-8. DOI: [10.1016/j.jad.2017.12.056](https://doi.org/10.1016/j.jad.2017.12.056). PubMed PMID: [29331703](https://pubmed.ncbi.nlm.nih.gov/29331703/).
66. Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Tan KHX, et al. Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: cross-sectional analysis of baseline data from PERFORM-J. *J Affect Disord.* 2019;258:172-8. DOI: [10.1016/j.jad.2019.07.064](https://doi.org/10.1016/j.jad.2019.07.064). PubMed PMID: [31426015](https://pubmed.ncbi.nlm.nih.gov/31426015/).
67. Nierenberg AA, Loft H, Olsen CK. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: a randomized, double-blinded, exploratory study with vortioxetine. *J Affect Disord.* 2019;250:35-42. DOI: [10.1016/j.jad.2019.02.006](https://doi.org/10.1016/j.jad.2019.02.006). PubMed PMID: [30826492](https://pubmed.ncbi.nlm.nih.gov/30826492/).
68. Ragguett R-M, Yim SJ, Ho PT, McIntyre RS. Efficacy of levomilnacipran extended release in treating major depressive disorder. *Expert Opin Pharmacother.* 2017;18(18):2017-24. DOI: [10.1080/14656566.2017.1410540](https://doi.org/10.1080/14656566.2017.1410540). PubMed PMID: [29195487](https://pubmed.ncbi.nlm.nih.gov/29195487/).
69. Moret C, Briley M. The importance of norepinephrine in depression. *Neuropsychiatr Dis Treat.* 2011;7(Suppl 1):9-13. DOI: [10.2147/NDT.S19619](https://doi.org/10.2147/NDT.S19619). PubMed PMID: [21750623](https://pubmed.ncbi.nlm.nih.gov/21750623/).
70. Freeman MP, Fava M, Gommoll C, Chen C, Greenberg WM, Ruth A. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder. *Int Clin Psychopharmacol.* 2016;31(2):100-9. DOI: [10.1097/YIC.000000000000104](https://doi.org/10.1097/YIC.000000000000104). PubMed PMID: [26584326](https://pubmed.ncbi.nlm.nih.gov/26584326/).
71. Ferguson M, Dennehy EB, Marangell LB, Martinez J, Wisniewski SR. Impact of fatigue on outcome of selective serotonin reuptake inhibitor treatment: secondary analysis of STAR\*D. *Curr Med Res Opin.* 2014;30(10):2109-18. DOI: [10.1185/03007995.2014.936553](https://doi.org/10.1185/03007995.2014.936553). PubMed PMID: [24949937](https://pubmed.ncbi.nlm.nih.gov/24949937/).
72. Lam RW, Michalak EE, Bond DJ, Tam EM, Axler A, Yatham LN. Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning? *Depress Res Treat.* 2012;2012:630206. DOI: [10.1155/2012/630206](https://doi.org/10.1155/2012/630206). PubMed PMID: [22611491](https://pubmed.ncbi.nlm.nih.gov/22611491/).
73. Mago R, Mahajan R, Thase ME. Levomilnacipran: a newly approved drug for treatment of major depressive disorder. *Expert Rev Clin Pharmacol.* 2014;7(2):137-45. DOI: [10.1586/17512433.2014.889563](https://doi.org/10.1586/17512433.2014.889563). PubMed PMID: [24524592](https://pubmed.ncbi.nlm.nih.gov/24524592/).
74. Levomilnacipran [package insert]. Madison (NJ): Allergan USA, Inc; 2009
75. Bruno A, Morabito P, Spina E, Muscatello MR. The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. *Curr Neuropharmacol.* 2016;14(2):191-9. DOI: [10.2174/1570159x14666151117122458](https://doi.org/10.2174/1570159x14666151117122458). PubMed PMID: [26572745](https://pubmed.ncbi.nlm.nih.gov/26572745/).
76. Auclair AL, Martel JC, Assié MB, Bardin L, Heusler P, Cussac D, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. *Neuropharmacology.* 2013;70:338-47. DOI: [10.1016/j.neuropharm.2013.02.024](https://doi.org/10.1016/j.neuropharm.2013.02.024). PubMed PMID: [23499664](https://pubmed.ncbi.nlm.nih.gov/23499664/).
77. Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry.* 2013;74(3):242-8. DOI: [10.4088/JCP.12m08197](https://doi.org/10.4088/JCP.12m08197). PubMed PMID: [23561229](https://pubmed.ncbi.nlm.nih.gov/23561229/).
78. Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, et al. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-

- dose, placebo-controlled study. *J Psychiatry Neurosci.* 2014;39(1):40-9. DOI: [10.1503/jpn.130040](https://doi.org/10.1503/jpn.130040). PubMed PMID: [24144196](https://pubmed.ncbi.nlm.nih.gov/24144196/).
79. Gommoll CP, Greenberg WM, Chen C. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. *J Drug Assess.* 2014;3(1):10-9. DOI: [10.3109/21556660.2014.884505](https://doi.org/10.3109/21556660.2014.884505). PubMed PMID: [27536449](https://pubmed.ncbi.nlm.nih.gov/27536449/).
80. Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. *J Clin Psychopharmacol.* 2014;34(1):47-56. DOI: [10.1097/JCP.0000000000000060](https://doi.org/10.1097/JCP.0000000000000060). PubMed PMID: [24172209](https://pubmed.ncbi.nlm.nih.gov/24172209/).
81. Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. *J Clin Psychiatry.* 2013;74(4):363-9. DOI: [10.4088/JCP.12m08141](https://doi.org/10.4088/JCP.12m08141). PubMed PMID: [23656841](https://pubmed.ncbi.nlm.nih.gov/23656841/).
82. Blier P, Gommoll C, Chen C, Kramer K. Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials. *J Affect Disord.* 2017;210:273-9. DOI: [10.1016/j.jad.2016.11.011](https://doi.org/10.1016/j.jad.2016.11.011). PubMed PMID: [28068615](https://pubmed.ncbi.nlm.nih.gov/28068615/).
83. Arakawa R, Stenkrona P, Takano A, Svensson J, Andersson M, Nag S, et al. Venlafaxine ER blocks the norepinephrine transporter in the brain of patients with major depressive disorder: a PET study using [<sup>18</sup>F]FMeNER-D2. *Int J Neuropsychopharmacol.* 2019;22(4):278-85. DOI: [10.1093/ijnp/pyz003](https://doi.org/10.1093/ijnp/pyz003). PubMed PMID: [30649319](https://pubmed.ncbi.nlm.nih.gov/30649319/).
84. Bosman RC, Waumans RC, Jacobs GE, Oude Voshaar RC, Muntingh ADT, Batelaan NM, et al. Failure to respond after reinstatement of antidepressant medication: a systematic review. *Psychother Psychosom.* 2018;87(5):268-75. DOI: [10.1159/000491550](https://doi.org/10.1159/000491550). PubMed PMID: [30041180](https://pubmed.ncbi.nlm.nih.gov/30041180/).
85. Wagner G, Schultes M-T, Titscher V, Teufer B, Klerings I, Gartlehner G. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: a systematic review and network meta-analysis. *J Affect Disord.* 2018;228:1-12. DOI: [10.1016/j.jad.2017.11.056](https://doi.org/10.1016/j.jad.2017.11.056). PubMed PMID: [29197738](https://pubmed.ncbi.nlm.nih.gov/29197738/).
86. McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. *Neuropsychiatr Dis Treat.* 2017;13:2913-9. DOI: [10.2147/NDT.S150589](https://doi.org/10.2147/NDT.S150589). PubMed PMID: [29238196](https://pubmed.ncbi.nlm.nih.gov/29238196/).